Douglass Winthrop Advisors LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,762 shares of the life sciences company’s stock after selling 518 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Illumina were worth $1,381,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Financial Gravity Wealth Inc. bought a new position in shares of Illumina during the 1st quarter valued at about $193,000. United Capital Financial Advisers LLC lifted its holdings in shares of Illumina by 6.4% during the 1st quarter. United Capital Financial Advisers LLC now owns 38,082 shares of the life sciences company’s stock valued at $9,003,000 after purchasing an additional 2,304 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Illumina by 21.9% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,154 shares of the life sciences company’s stock valued at $3,817,000 after purchasing an additional 2,903 shares in the last quarter. LPL Financial LLC lifted its holdings in shares of Illumina by 38.6% during the 1st quarter. LPL Financial LLC now owns 9,228 shares of the life sciences company’s stock valued at $2,182,000 after purchasing an additional 2,568 shares in the last quarter. Finally, Sciencast Management LP bought a new position in shares of Illumina during the 1st quarter valued at about $379,000. Hedge funds and other institutional investors own 89.84% of the company’s stock.
Several research firms have recently weighed in on ILMN. Deutsche Bank lifted their price objective on Illumina to $350.00 and gave the company a “buy” rating in a report on Friday. ValuEngine cut Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday. UBS Group initiated coverage on Illumina in a research note on Tuesday. They issued a “neutral” rating and a $340.00 target price on the stock. BidaskClub cut Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Finally, Piper Jaffray Companies boosted their target price on Illumina to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, October 2nd. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $324.76.
In other Illumina news, Director Robert S. Epstein sold 500 shares of the business’s stock in a transaction that occurred on Monday, July 23rd. The stock was sold at an average price of $311.15, for a total transaction of $155,575.00. Following the transaction, the director now owns 6,139 shares of the company’s stock, valued at approximately $1,910,149.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, October 10th. The stock was sold at an average price of $321.58, for a total value of $1,061,214.00. Following the transaction, the director now directly owns 385,604 shares in the company, valued at approximately $124,002,534.32. The disclosure for this sale can be found here. Insiders have sold a total of 52,483 shares of company stock worth $17,702,063 in the last ninety days. Insiders own 0.54% of the company’s stock.
NASDAQ ILMN opened at $321.69 on Friday. The company has a market capitalization of $53.96 billion, a price-to-earnings ratio of 80.42, a PEG ratio of 3.04 and a beta of 0.97. The company has a current ratio of 2.74, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22. Illumina, Inc. has a 52 week low of $198.21 and a 52 week high of $372.61.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.32. The firm had revenue of $830.00 million for the quarter, compared to analyst estimates of $786.88 million. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The business’s quarterly revenue was up 25.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.82 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.46 EPS for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Story: Conference Calls
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.